01—Abstract
Summary
Summary of the 8-K filed August 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Amgen (AMGN) reported Q2 2025 results that beat on the top and bottom line, with total revenues up 9% to $9.2 billiona, driven by 13% volume growth partially offset by 3% lower net selling price.
Product sales reached $8.77 billionb, and 15 products grew at least double digits, led by Repatha, EVENITY, IMDELLTRA, BLINCYTO, TEZSPIRE, UPLIZNA and TAVNEOS. GAAP diluted EPS rose 92% to $2.65 from $1.38, and non-GAAP EPS rose 21% to $6.02 from $4.97. The GAAP improvement is flattered by lower acquisition-related amortization tied to Horizon and by a $591 million unrealized loss on equity investments, which is excluded from non-GAAP results, so investors should weigh the two measures together.
Profitability and cash generation were mixed. Non-GAAP operating margin expanded 0.7 points to 48.9%, but free cash flow fell to $1.9 billionc from $2.2 billion, reflecting 2024 tax payments shifted into 2025 and higher capex. Operating cash flow was $2.3 billion.
Debt was reduced by $1.4 billiond in the quarter and $4.3 billion year to date, bringing debt outstanding to $56.2 billion against $8.0 billion of cash. No shares were repurchased in the quarter. Pricing pressure is visible in Enbrel, which fell 34% on 340B mix and Medicare Part D redesign, and in Prolia and XGEVA, which face biosimilar erosion in the second half.
Management reaffirmed or set 2025 guidance of $35.0–36.0 billion in revenue, GAAP EPS of $10.97–12.11, and non-GAAP EPS of $20.20–21.30. The guidance excludes unimplemented tariffs and pricing actions. The pipeline news flow is heavy in the second half, with the MariTide Part 2 and T2D readouts expected in Q4 2025, VESALIUS-CV for Repatha in H2 2025, the UPLIZNA PDUFA date on December 14, 2025, and the TEZSPIRE CRSwNP PDUFA date on October 19, 2025.
02—Key points
Key Highlights
- Total revenues rose 9% year over year to $9.2 billion, with product sales of $8.77 billion up 9%, driven by 13% volume growth offset by 3% lower net selling price.
- GAAP diluted EPS rose 92% to $2.65 (from $1.38), while non-GAAP diluted EPS rose 21% to $6.02 (from $4.97). The GAAP gain is aided by lower Horizon-related amortization, and GAAP results include a $591 million equity investment loss that non-GAAP excludes.
- Non-GAAP operating margin expanded 0.7 points to 48.9% of product sales, while GAAP operating margin rose 6.6 points to 30.3%.
- Free cash flow fell to $1.9 billion from $2.2 billion, due to timing of 2024 tax payments moved into 2025 and higher capital expenditures ($369 million versus $238 million).
- Growth leaders included Repatha (+31%), EVENITY (+32%), BLINCYTO (+45%), TEZSPIRE (+46%), and IMDELLTRA ($134 million), while Enbrel fell 34% to $604 million on pricing and 340B mix.
- FY2025 guidance: revenue of $35.0–36.0 billion, non-GAAP EPS of $20.20–21.30, GAAP EPS of $10.97–12.11, capex of about $2.3 billion, and buybacks capped at $500 million. Guidance excludes unimplemented tariffs and pricing actions.
- Balance sheet: $1.4 billion of debt retired in Q2 ($4.3 billion year to date), with $56.2 billion of debt outstanding and $8.0 billion of cash at June 30, 2025. No share repurchases were made in the quarter.
03—Questions
Frequently Asked Questions
Why is GAAP EPS growth (92%) so much higher than non-GAAP EPS growth (21%)?
The GAAP figure benefits from a sharp drop in acquisition-related amortization and fair value step-up of inventory tied to Horizon, which cut GAAP cost of sales by 7% and lifted GAAP operating margin. Non-GAAP excludes these charges, so the gap narrows. Non-GAAP EPS also reflects higher R&D spending, up 18%, for MariTide and other late-stage programs, and GAAP and non-GAAP tax rates moved in opposite directions.
Why did free cash flow decline despite higher revenue?
Free cash flow fell to $1.9 billion from $2.2 billion mainly because 2024 tax payments were deferred into 2025 and capital expenditures rose to $369 million from $238 million. Operating cash flow was $2.3 billion, down from $2.5 billion. Management attributed the decline to timing and investment, not to a deterioration in underlying business performance.
What are the main risks to Amgen's revenue outlook for the rest of 2025?
Key risks include biosimilar erosion for Prolia and XGEVA in the second half, continued pricing pressure on Enbrel from 340B mix and Medicare Part D changes, and expected normalization of MVASI after competitor shortages. Guidance also excludes any future tariffs or pricing actions not yet implemented, so those represent additional downside risk.
What catalysts should investors watch in the second half of 2025?
Near-term catalysts include the TEZSPIRE CRSwNP FDA decision (PDUFA October 19, 2025), the UPLIZNA generalized myasthenia gravis PDUFA date (December 14, 2025), and VESALIUS-CV for Repatha (event-driven, H2 2025). Q4 2025 brings MariTide Part 2 and type 2 diabetes Phase 2 readouts, and the ABP 206 biosimilar study and the rocatinlimab ROCKET ASCEND and ASTRO readouts are expected in H2 2025.
How is Amgen managing its debt and capital allocation?
Amgen retired $4.3 billion of debt year to date, reducing total debt from $60.1 billion at year-end 2024 to $56.2 billion. It paid $1.3 billion in dividends in the quarter (a $2.38 per-share dividend, up 6%) and made no share repurchases. Guidance permits buybacks of up to $500 million for the full year, so deleveraging appears to be the priority.
04—Continue